GlassScriptPhysician profile
Cesar O Torres
NPI 1346466943
$19,954.75
in general payments reported to CMS, 2019-2025
51 companies · $26.92 in 2025
The $26.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,032 · 2021: $2,229 · 2022: $2,399 · 2023: $995 · 2024: $95.07 · 2025: $26.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,816.95 | 2019-2023 | |
| Novo Nordisk INC | $1,554.71 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,036.99 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $836.73 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $812.53 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $689.98 | 2019-2022 | |
| Abbvie INC. | $583.38 | 2019-2023 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $492.48 | 2019-2022 | |
| Gilead Sciences, INC. | $438.46 | 2020-2023 | |
| Amgen INC. | $287.56 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $234.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.96 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $136.84 | 2021-2023 | |
| Abbott Laboratories | $128.32 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.45 | 2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.